The Journal of Heart and Lung Transplantation
Volume 29, Issue 8 , Pages 914-956 , August 2010

The International Society of Heart and Lung Transplantation Guidelines for the care of heart transplant recipients

References 

  1. Young JB, Hauptman PJ, Naftel DC, et al. Determinants of early graft failure following cardiac transplantation, a 10-year, multi-institutional, multivariable analysis. J Heart Lung Transplant. 2001;20:212
  2. Lietz K, John R, Mancini DM, Edwards NM. Outcomes in cardiac transplant recipients using allografts from older donors versus mortality on the transplant waiting list; implications for donor selection criteria. J Am Coll Cardiol. 2004;43:1553–1561
  3. Kubak BM, Gregson AL, Pegues DA, et al. Use of hearts transplanted from donors with severe sepsis and infectious deaths. J Heart Lung Transplant. 2009;28:260–265
  4. Brieke A, Krishnamani R, Rocha MJ, et al. Influence of donor cocaine use on outcome after cardiac transplantation: analysis of the United Network for Organ Sharing Thoracic Registry. J Heart Lung Transplant. 2008;27:1350–1352
  5. De La Zerda DJ, Cohen O, Beygui RE, et al. Alcohol use in donors is a protective factor on recipients' outcome after heart transplantation. Transplantation. 2007;83:1214–1218
  6. Smith JA, Bergin PJ, Williams TJ, Esmore DS. Successful heart transplantation with cardiac allografts exposed to carbon monoxide poisoning. J Heart Lung Transplant. 1992;11:698–700
  7. Snyder JW, Unkle DW, Nathan HM, Yang SL. Successful donation and transplantation of multiple organs from a victim of cyanide poisoning. Transplantation. 1993;55:425–427
  8. Navia JL, Atik FA, Marullo A, et al. Bench repair of donor aortic valve with minimal access orthotopic heart transplantation. Ann Thorac Surg. 2005;80:313–315
  9. Laks H, Scholl FG, Drinkwater DC, et al. The alternate recipient list for heart transplantation: does it work?. J Heart Lung Transplant. 1997;16:735–742
  10. Young JB, Naftel DC, Bourge RC, et al. Matching the heart donor and heart transplant recipient (Clues for successful expansion of the donor pool: a multivariable, multiinstitutional report. The Cardiac Transplant Research Database Group). J Heart Lung Transplant. 1994;13:353–364
  11. Blackbourne LH, Tribble CG, Langenburg SE, et al. Successful use of undersized donors for orthotopic heart transplantation—with a caveat. Ann Thorac Surg. 1994;57:1472–1475
  12. Sethi GK, Lanauze P, Rosado LJ, et al. Clinical significance of weight difference between donor and recipient in heart transplantation. J Thorac Cardiovasc Surg. 1993;106:444–448
  13. Bull DA, Stahl RD, McMahan DL, et al. The high risk heart donor: potential pitfalls. J Heart Lung Transplant. 1995;14:424–428
  14. Mackintosh AF, Carmichael DJ, Wren C, Cory-Pearce R, English TA. Sinus node function in first three weeks after cardiac transplantation. Br Heart J. 1982;48:584–588
  15. Leonelli FM, Pacifico A, Young JB. Frequency and significance of conduction defects early after orthotopic heart transplantation. Am J Cardiol. 1994;73:175–179
  16. Leeman M, Van CM, Vachiery JL, Antoine M, Leclerc JL. Determinants of right ventricular failure after heart transplantation. Acta Cardiol. 1996;51:441–449
  17. Kimball TR, Witt SA, Daniels SR, Khoury PR, Meyer RA. Frequency and significance of left ventricular thickening in transplanted hearts in children. Am J Cardiol. 1996;77:77–80
  18. Mahle WT, Cardis BM, Ketchum D, et al. Reduction in initial ventricular systolic and diastolic velocities after heart transplantation in children: improvement over time identified by tissue Doppler imaging. J Heart Lung Transplant. 2006;25:1290–1296
  19. Asante-Korang A, Fickey M, Boucek MM, Boucek RJ. Diastolic performance assessed by tissue Doppler after pediatric heart transplantation. J Heart Lung Transplant. 2004;23:865–872
  20. Stinson EB, Caves PK, Griepp RB, et al. Hemodynamic observations in the early period after human heart transplantation. J Thorac Cardiovasc Surg. 1975;69:264–270
  21. Rothman SA, Jeevanandam V, Combs WG, et al. Eliminating bradyarrhythmias after orthotopic heart transplantation. Circulation. 1996;94(9 suppl):II278–II282
  22. Zieroth S, Ross H, Rao V, et al. Permanent pacing after cardiac transplantation in the era of extended donors. J Heart Lung Transplant. 2006;25:1142–1147
  23. Costanzo-Nordin MR, Liao YL, Grusk BB, et al. Oversizing of donor hearts: beneficial or detrimental?. J Heart Lung Transplant. 1991;10:717–730
  24. Minev PA, El-Banayosy A, Minami K, et al. Differential indication for mechanical circulatory support following heart transplantation. Intensive Care Med. 2001;27:1321–1327
  25. Ibrahim M, Hendry P, Masters R, et al. Management of acute severe perioperative failure of cardiac allografts: a single-centre experience with a review of the literature. Can J Cardiol. 2007;23:363–367
  26. Santise G, Petrou M, Pepper JR, et al. Levitronix as a short-term salvage treatment for primary graft failure after heart transplantation. J Heart Lung Transplant. 2006;25:495–498
  27. Huang J, Trinkaus K, Huddleston CB, et al. Risk factors for primary graft failure after pediatric cardiac transplantation: importance of recipient and donor characteristics. J Heart Lung Transplant. 2004;23:716–722
  28. Mehra MR, Kobashigawa J, Starling R, et al. Listing criteria for heart transplantation: International Society for Heart and Lung Transplantation guidelines for the care of cardiac transplant candidates—2006. J Heart Lung Transplant. 2006;25:1024–2
  29. Bhatia SJ, Kirshenbaum JM, Shemin RJ, et al. Time course of resolution of pulmonary hypertension and right ventricular remodeling after orthotopic cardiac transplantation. Circulation. 1987;76:819–826
  30. Stobierska-Dzierzek B, Awad H, Michler RE. The evolving management of acute right-sided heart failure in cardiac transplant recipients. J Am Coll Cardiol. 2001;38:923–931
  31. Kieler-Jensen N, Lundin S, Ricksten SE. Vasodilator therapy after heart transplantation: effects of inhaled nitric oxide and intravenous prostacyclin, prostaglandin E1, and sodium nitroprusside. J Heart Lung Transplant. 1995;14:436–443
  32. Jeevanandam V, Russell H, Mather P, et al. Donor tricuspid annuloplasty during orthotopic heart transplantation: long-term results of a prospective controlled study. Ann Thorac Surg. 2006;82:2089–2095
  33. Wong RC, Abrahams Z, Hanna M, et al. Tricuspid regurgitation after cardiac transplantation: an old problem revisited. J Heart Lung Transplant. 2008;27:247–252
  34. Hauptman PJ, Couper GS, Aranki SF, et al. Pericardial effusions after cardiac transplantation. J Am Coll Cardiol. 1994;23:1625–1629
  35. Quin JA, Tauriainen MP, Huber LM, et al. Predictors of pericardial effusion after orthotopic heart transplantation. J Thorac Cardiovasc Surg. 2002;124:979–983
  36. Chen EP, Bittner HB, Davis RD, Van TP. Hemodynamic and inotropic effects of milrinone after heart transplantation in the setting of recipient pulmonary hypertension. J Heart Lung Transplant. 1998;17:669–678
  37. Leyh RG, Kofidis T, Struber M, et al. Methylene blue: the drug of choice for catecholamine-refractory vasoplegia after cardiopulmonary bypass?. J Thorac Cardiovasc Surg. 2003;125:1426–1431
  38. Argenziano M, Choudhri AF, Oz MC, et al. A prospective randomized trial of arginine vasopressin in the treatment of vasodilatory shock after left ventricular assist device placement. Circulation. 1997;96(9 suppl):II-90
  39. Morales DL, Garrido MJ, Madigan JD, et al. A double-blind randomized trial: prophylactic vasopressin reduces hypotension after cardiopulmonary bypass. Ann Thorac Surg. 2003;75:926–930
  40. Armitage JM, Hardesty RL, Griffith BP. Prostaglandin E1: an effective treatment of right heart failure after orthotopic heart transplantation. J Heart Transplant. 1987;6:348–351
  41. Pascual JM, Fiorelli AI, Bellotti GM, Stolf NA, Jatene AD. Prostacyclin in the management of pulmonary hypertension after heart transplantation. J Heart Transplant. 1990;9:644–651
  42. Theodoraki K, Tsiapras D, Tsourelis L, et al. Inhaled iloprost in eight heart transplant recipients presenting with post-bypass acute right ventricular dysfunction. Acta Anaesthesiol Scand. 2006;50:1213–1217
  43. Ardehali A, Hughes K, Sadeghi A, et al. Inhaled nitric oxide for pulmonary hypertension after heart transplantation. Transplantation. 2001;72:638–641
  44. Auler Junior JO, Carmona MJ, Bocchi EA, et al. Low doses of inhaled nitric oxide in heart transplant recipients. J Heart Lung Transplant. 1996;15:443–450
  45. De Santo LS, Mastroianni C, Romano G, et al. Role of sildenafil in acute posttransplant right ventricular dysfunction: successful experience in 13 consecutive patients. Transplant Proc. 2008;40:2015–2018
  46. Kirklin JK, Young JB, McGiffin DC. Heart transplantation. Philadelphia: Churchill Livingstone; 2002;
  47. Haddad F, Hunt SA, Rosenthal DN, Murphy DJ. Right ventricular function in cardiovascular disease, part I: anatomy, physiology, aging, and functional assessment of the right ventricle. Circulation. 2008;117:1436–1448
  48. Arafa OE, Geiran OR, Andersen K, et al. Intraaortic balloon pumping for predominantly right ventricular failure after heart transplantation. Ann Thorac Surg. 2000;70:1587–1593
  49. Jurmann MJ, Wahlers T, Coppola R, Fieguth HG, Haverich A. Early graft failure after heart transplantation: management by extracorporeal circulatory assist and retransplantation. J Heart Transplant. 1989;8:474–478
  50. Tenderich G, Koerner MM, Stuettgen B, et al. Mechanical circulatory support after orthotopic heart transplantation. Int J Artif Organs. 1998;21:414–416
  51. Barnard SP, Hasan A, Forty J, Hilton CJ, Dark JH. Mechanical ventricular assistance for the failing right ventricle after cardiac transplantation. Eur J Cardiothorac Surg. 1995;9:297–299
  52. Chen JM, Levin HR, Rose EA, et al. Experience with right ventricular assist devices for perioperative right-sided circulatory failure. Ann Thorac Surg. 1996;61:305–310
  53. Costard-Jackle A, Fowler MB. Influence of preoperative pulmonary artery pressure on mortality after heart transplantation: testing of potential reversibility of pulmonary hypertension with nitroprusside is useful in defining a high risk group. J Am Coll Cardiol. 1992;19:48–54
  54. Bourge RC, Naftel DC, Costanzo-Nordin MR, et al. Pretransplantation risk factors for death after heart transplantation: a multiinstitutional study (The Transplant Cardiologists Research Database Group). J Heart Lung Transplant. 1993;12:549–562
  55. Chen JM, Levin HR, Michler RE, et al. Reevaluating the significance of pulmonary hypertension before cardiac transplantation: determination of optimal thresholds and quantification of the effect of reversibility on perioperative mortality. J Thorac Cardiovasc Surg. 1997;114:627–634
  56. Erickson KW, Costanzo-Nordin MR, O'Sullivan EJ, et al. Influence of preoperative transpulmonary gradient on late mortality after orthotopic heart transplantation. J Heart Transplant. 1990;9:526–537
  57. Bando K, Konishi H, Komatsu K, et al. Improved survival following pediatric cardiac transplantation in high-risk patients. Circulation. 1993;88:II218–II223
  58. Bauer J, Dapper F, Demirakca S, et al. Perioperative management of pulmonary hypertension after heart transplantation in childhood. J Heart Lung Transplant. 1997;16:1238–1247
  59. Addonizio LJ, Gersony WM, Robbins RC, et al. Elevated pulmonary vascular resistance and cardiac transplantation. Circulation. 1987;76:V52–V55
  60. Bailey LL, Gundry SR, Razzouk AJ, et al. Bless the babies: one hundred fifteen late survivors of heart transplantation during the first year of life (The Loma Linda University Pediatric Heart Transplant Group). J Thorac Cardiovasc Surg. 1993;105:805–814
  61. Stecker EC, Strelich KR, Chugh SS, Crispell K, McAnulty JH. Arrhythmias after orthotopic heart transplantation. J Card Fail. 2005;11:464–472
  62. Gao SZ, Hunt SA, Wiederhold V, Schroeder JS. Characteristics of serial electrocardiograms in heart transplant recipients. Am Heart J. 1991;122:771–774
  63. Holt ND, McComb JM. Cardiac transplantation and pacemakers: when and what to implant. Card Electrophysiol Rev. 2002;6:140–151
  64. Miyamoto Y, Curtiss EI, Kormos RL, et al. Bradyarrhythmia after heart transplantation (Incidence, time course, and outcome). Circulation. 1990;82(5 Suppl):IV313–IV317
  65. Pavri BB, O'Nunain SS, Newell JB, Ruskin JN, William G. Prevalence and prognostic significance of atrial arrhythmias after orthotopic cardiac transplantation. J Am Coll Cardiol. 1995;25:1673–1680
  66. Vaseghi M, Boyle NG, Kedia R, et al. Supraventricular tachycardia after orthotopic cardiac transplantation. J Am Coll Cardiol. 2008;51:2241–2249
  67. Ellenbogen KA, Thames MD, DiMarco JP, Sheehan H, Lerman BB. Electrophysiological effects of adenosine in the transplanted human heart (Evidence of supersensitivity). Circulation. 1990;81:821–828
  68. Rubel JR, Milford EL, McKay DB, Jarcho JA. Renal insufficiency and end-stage renal disease in the heart transplant population. J Heart Lung Transplant. 2004;23:289–300
  69. Costanzo MR, Guglin ME, Saltzberg MT, et al. Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure. J Am Coll Cardiol. 2007;49:675–683
  70. Boyle JM, Moualla S, Arrigain S, et al. Risks and outcomes of acute kidney injury requiring dialysis after cardiac transplantation. Am J Kidney Dis. 2006;48:787–796
  71. Anselm A, Cantarovich M, Davies R, Grenon J, Haddad H. Prolonged basiliximab use as an alternative to calcineurin inhibition to allow renal recovery late after heart transplantation. J Heart Lung Transplant. 2008;27:1043–1045
  72. Furnary AP, Gao G, Grunkemeier GL, et al. Continuous insulin infusion reduces mortality in patients with diabetes undergoing coronary artery bypass grafting. J Thorac Cardiovasc Surg. 2003;125:1007–1021
  73. Wilson M, Weinreb J, Hoo GW. Intensive insulin therapy in critical care: a review of 12 protocols. Diabetes Care. 2007;30:1005–1011
  74. Hawkins JA, Breinholt JP, Lambert LM, et al. Class I and class II anti-HLA antibodies after implantation of cryopreserved allograft material in pediatric patients. J Thorac Cardiovasc Surg. 2000;119:324–330
  75. Pagani FD, Dyke DB, Wright S, Cody R, Aaronson KD. Development of anti-major histocompatibility complex class I or II antibodies following left ventricular assist device implantation: effects on subsequent allograft rejection and survival. J Heart Lung Transplant. 2001;20:646–653
  76. Feingold B, Bowman P, Zeevi A, et al. Survival in allosensitized children after listing for cardiac transplantation. J Heart Lung Transplant. 2007;26:565–1
  77. Pollack-BarZiv SM, den Hollander N, Ngan B-Y, et al. Pediatric heart transplantation in HLA-sensitized patients: evolving management and assessment of intermediate-term outcomes in a high-risk population. Circulation. 2007;116(11 suppl):172–178
  78. Betkowski AS, Graff R, Chen JJ, Hauptman PJ. Panel-reactive antibody screening practices prior to heart transplantation. J Heart Lung Transplant. 2002;21:644–650
  79. Tambur AR, Pamboukian SV, Costanzo MR, et al. The presence of HLA-directed antibodies after heart transplantation is associated with poor allograft outcome. Transplantation. 2005;80:1019–1025
  80. Kobashigawa J, Mehra M, West L, et al. Report from a consensus conference on the sensitized patient awaiting heart transplantation. J Heart Lung Transplant. 2009;28:213–225
  81. Gebel HM, Bray RA, Nickerson P. Pre-transplant assessment of donor-reactive, HLA-specific antibodies in renal transplantation: contraindication vs. risk. Am J Transplant. 2003;3:1488–1500
  82. Zangwill S, Ellis T, Stendahl G, et al. Practical application of the virtual crossmatch. Pediatr Transplant. 2007;11:650–654
  83. Pei R, Lee JH, Shih NJ, Chen M, Terasaki PI. Single human leukocyte antigen flow cytometry beads for accurate identification of human leukocyte antigen antibody specificities. Transplantation. 2003;75:43–49
  84. Vaidya S. Clinical importance of anti-human leukocyte antigen-specific antibody concentration in performing calculated panel reactive antibody and virtual crossmatches. Transplantation. 2008;85:1046–1050
  85. Takemoto SK, Zeevi A, Feng S, et al. National conference to assess antibody-mediated rejection in solid organ transplantation. Am J Transplant. 2004;4:1033–1041
  86. Pisani BA, Mullen GM, Malinowska K, et al. Plasmapheresis with intravenous immunoglobulin G is effective in patients with elevated panel reactive antibody prior to cardiac transplantation. J Heart Lung Transplant. 1999;18:701–706
  87. Holt DB, Lublin DM, Phelan DL, et al. Mortality and morbidity in pre-sensitized pediatric heart transplant recipients with a positive donor crossmatch utilizing peri-operative plasmapheresis and cytolytic therapy. J Heart Lung Transplant. 2007;26:876–882
  88. West LJ, Pollock-Barziv SM, Dipchand AI, et al. ABO-incompatible heart transplantation in infants. N Engl J Med. 2001;344:793–800
  89. Roche SL, Burch M, O'Sullivan J, et al. Multicenter experience of ABO-incompatible pediatric cardiac transplantation. Am J Transplant. 2008;8:208–215
  90. West LJ, Karamlou T, Dipchand AI, et al. Impact on outcomes after listing and transplantation, of a strategy to accept ABO blood group-incompatible donor hearts for neonates and infants. J Thorac Cardiovasc Surg. 2006;131:455–461
  91. Dipchand AI, Benson L, McCrindle BW, Coles J, West L. Mycophenolate mofetil in pediatric heart transplant recipients: a single-center experience. Pediatr Transplant. 2001;5:112–118
  92. Chee YL, Crawford JC, Watson HG, Greaves M. Guidelines on the assessment of bleeding risk prior to surgery or invasive procedures (British Committee for Standards in Haematology). Br J Haematol. 2008;140:496–504
  93. Hirsh J. Reversal of the anticoagulant effects of warfarin by vitamin K1. Chest. 1998;114:1505–1508
  94. Hanley JP. Warfarin reversal. J Clin Pathol. 2004;57:1132–1139
  95. Leissinger CA, Blatt PM, Hoots WK, Ewenstein B. Role of prothrombin complex concentrates in reversing warfarin anticoagulation: a review of the literature. Am J Hematol. 2008;83:137–143
  96. Schulman S, Bijsterveld NR. Anticoagulants and their reversal. Transfus Med Rev. 2007;21:37–48
  97. Warkentin TE, Greinacher A, Koster A, Lincoff AM. Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th ed). Chest. 2008;133(6 suppl):340–380S
  98. Selleng S, Haneya A, Hirt S, et al. Management of anticoagulation in patients with subacute heparin-induced thrombocytopenia scheduled for heart transplantation. Blood. 2008;112:4024–4027
  99. Pamboukian SV, Ignaszewski AP, Ross HJ. Management strategies for heparin-induced thrombocytopenia in heart-transplant candidates: case report and review of the literature. J Heart Lung Transplant. 2000;19:810–814
  100. Laupacis A, Fergusson D. Drugs to minimize perioperative blood loss in cardiac surgery: meta-analyses using perioperative blood transfusion as the outcome (The International Study of Perioperative Transfusion (ISPOT) Investigators). Anesth Analg. 1997;85:1258–1267
  101. Karkouti K, Beattie WS, Dattilo KM, et al. A propensity score case-control comparison of aprotinin and tranexamic acid in high-transfusion-risk cardiac surgery. Transfusion (Paris). 2006;46:327–338
  102. Mahdy AM, Webster NR. Perioperative systemic haemostatic agents. Br J Anaesth. 2004;93:842–858
  103. Reid RW, Zimmerman AA, Laussen PC, et al. The efficacy of tranexamic acid versus placebo in decreasing blood loss in pediatric patients undergoing repeat cardiac surgery. Anesth Analg. 1997;84:990–996
  104. Levi M, Cromheecke ME, de JE, et al. Pharmacological strategies to decrease excessive blood loss in cardiac surgery: a meta-analysis of clinically relevant endpoints. Lancet. 1999;354:1940–1947
  105. Cattaneo M, Harris AS, Stromberg U, Mannucci PM. The effect of desmopressin on reducing blood loss in cardiac surgery—a meta-analysis of double-blind, placebo-controlled trials. Thromb Haemost. 1995;74:1064–1070
  106. Steinman TI, Becker BN, Frost AE, et al. Guidelines for the referral and management of patients eligible for solid organ transplantation. Transplantation. 2001;71:1189–1204
  107. Dobbels F, Vanhaecke J, Desmyttere A, et al. Prevalence and correlates of self-reported pretransplant nonadherence with medication in heart, liver, and lung transplant candidates. Transplantation. 2005;79:1588–1595
  108. Martin JE, Zavala EY. The expanding role of the transplant pharmacist in the multidisciplinary practice of transplantation. Clin Transplant. 2004;18(suppl 12):50–54
  109. Canter C, Naftel D, Caldwell R, et al. Survival and risk factors for death after cardiac transplantation in infants (A multi-institutional study. The Pediatric Heart Transplant Study). Circulation. 1997;96:227–231
  110. Frazier EA, Naftel D, Canter C, et al. Death after cardiac transplantation in children: who dies, when, and why. J Heart Lung Transplant. 1999;18:69–70
  111. Kirshbom PM, Bridges ND, Myung RJ, et al. Use of extracorporeal membrane oxygenation in pediatric thoracic organ transplantation. J Thorac Cardiovasc Surg. 2002;123:130–136
  112. Fenton KN, Webber SA, Danford DA, et al. Long-term survival after pediatric cardiac transplantation and postoperative ECMO support. Ann Thorac Surg. 2003;76:843–846
  113. Mitchell MB, Campbell DN, Bielefeld MR, Doremus T. Utility of extracorporeal membrane oxygenation for early graft failure following heart transplantation in infancy. J Heart Lung Transplant. 2000;19:834–839
  114. Huddleston CB, Thul JM. Postoperative management: early graft failure, pulmonary hypertension, and initial immunosuppression strategies (Chapter 7). In:  Canter CE,  Kirklin JK editor. ISHLT monograph series volume 2: pediatric heart transplantation. Addison, TX: ISHLT; 2007;
  115. Duncan BW. Pediatric mechanical circulatory support. ASAIO J. 2005;51:ix–xiv
  116. Seib PM, Faulkner SC, Erickson CC, et al. Blade and balloon atrial septostomy for left heart decompression in patients with severe ventricular dysfunction on extracorporeal membrane oxygenation. Catheter Cardiovasc Interv. 1999;46:179–186
  117. Fiser SM, Tribble CG, Kaza AK, et al. When to discontinue extracorporeal membrane oxygenation for postcardiotomy support. Ann Thorac Surg. 2001;71:210–214
  118. Cooper LT, Baughman KL, Feldman AM, et al. The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology (Endorsed by the Heart Failure Society of America and the Heart Failure Association of the European Society of Cardiology). J Am Coll Cardiol. 2007;50:1914–1931
  119. Stehlik J, Starling RC, Movsesian MA, et al. Utility of long-term surveillance endomyocardial biopsy: a multi-institutional analysis. J Heart Lung Transplant. 2006;25:1402–1409
  120. Rosenthal DN, Chin C, Nishimura K, et al. Identifying cardiac transplant rejection in children: diagnostic utility of echocardiography, right heart catheterization and endomyocardial biopsy data. J Heart Lung Transplant. 2004;23:323–329
  121. Kemkes BM, Schutz A, Engelhardt M, Brandl U, Breuer M. Noninvasive methods of rejection diagnosis after heart transplantation. J Heart Lung Transplant. 1992;11:S221–S231
  122. Horenstein MS, Idriss SF, Hamilton RM, et al. Efficacy of signal-averaged electrocardiography in the young orthotopic heart transplant patient to detect allograft rejection. Pediatr Cardiol. 2006;27:589–593
  123. Schweiger M, Wasler A, Prenner G, et al. The prognostic validity of the ventricular evoked response (VER) signals in cardiac transplantation. J Heart Lung Transplant. 2005;24:1730–1735
  124. Butler CR, Thompson R, Haykowsky M, Toma M, Paterson I. Cardiovascular magnetic resonance in the diagnosis of acute heart transplant rejection: a review. J Cardiovasc Magn Reson. 2009;11:7
  125. Marie PY, Angioi M, Carteaux JP, et al. Detection and prediction of acute heart transplant rejection with the myocardial T2 determination provided by a black-blood magnetic resonance imaging sequence. J Am Coll Cardiol. 2001;37:825–831
  126. Geiger M, Harake D, Halnon N, Alejos JC, Levi DS. Screening for rejection in symptomatic pediatric heart transplant recipients: the sensitivity of BNP. Pediatr Transplant. 2008;12:563–569
  127. Dengler TJ, Zimmermann R, Braun K, et al. Elevated serum concentrations of cardiac troponin T in acute allograft rejection after human heart transplantation. J Am Coll Cardiol. 1998;32:405–412
  128. Arora S, Gullestad L, Wergeland R, et al. Probrain natriuretic peptide and C-reactive protein as markers of acute rejection, allograft vasculopathy, and mortality in heart transplantation. Transplantation. 2007;83:1308–1315
  129. Dengler TJ, Gleissner CA, Klingenberg R, et al. Biomarkers after heart transplantation: nongenomic. Heart Fail Clin. 2007;3:69–81
  130. Azzawi M, Hasleton PS, Turner DM, et al. Tumor necrosis factor-alpha gene polymorphism and death due to acute cellular rejection in a subgroup of heart transplant recipients. Hum Immunol. 2001;62:140–142
  131. Keslar K, Rodriguez ER, Tan CD, Starling RC, Heeger PS. Complement gene expression in human cardiac allograft biopsies as a correlate of histologic grade of injury. Transplantation. 2008;86:1319–1321
  132. Deng MC, Eisen HJ, Mehra MR, et al. Noninvasive discrimination of rejection in cardiac allograft recipients using gene expression profiling. Am J Transplant. 2006;6:150–160
  133. Pham MX, Teuteberg JJ, Kfoury AG, et al. Gene-expression profiling for rejection surveillance after cardiac transplantation. N Engl J Med. 2010;362:1890–1900
  134. Rossano JW, Denfield SW, Kim JJ, et al. B-type natriuretic peptide is a sensitive screening test for acute rejection in pediatric heart transplant patients. J Heart Lung Transplant. 2008;27:649–654
  135. Bennhagen RG, Sornmo L, Pahlm O, Pesonen E. Serial signal-averaged electrocardiography in children after cardiac transplantation. Pediatr Transplant. 2005;9:773–779
  136. Lindenfeld J, Miller GG, Shakar SF, et al. Drug therapy in the heart transplant recipient: part II: immunosuppressive drugs. Circulation. 2004;110:3858–3865
  137. Cantarovich M, Ross H, Arizon JM, et al. Benefit of Neoral C2 monitoring in de novo cardiac transplant recipients receiving basiliximab induction. Transplantation. 2008;85:992–999
  138. Barnard JB, Thekkudan J, Richardson S, et al. Cyclosporine profiling with C2 and C0 monitoring improves outcomes after heart transplantation. J Heart Lung Transplant. 2006;25:564–568
  139. Langers P, Press RR, den HJ, et al. Flexible limited sampling model for monitoring tacrolimus in stable patients having undergone liver transplantation with samples 4 to 6 hours after dosing is superior to trough concentration. Ther Drug Monit. 2008;30:456–461
  140. Tsunoda SM, Aweeka FT. Drug concentration monitoring of immunosuppressive agents: focus on tacrolimus, mycophenolate mofetil and sirolimus. BioDrugs. 2000;14:355–369
  141. Knight SR, Morris PJ. Does the evidence support the use of mycophenolate mofetil therapeutic drug monitoring in clinical practice? (A systematic review). Transplantation. 2008;85:1675–1685
  142. Stenton SB, Partovi N, Ensom MH. Sirolimus: the evidence for clinical pharmacokinetic monitoring. Clin Pharmacokinet. 2005;44:769–786
  143. Brandhorst G, Tenderich G, Zittermann A, et al. Everolimus exposure in cardiac transplant recipients is influenced by concomitant calcineurin inhibitor. Ther Drug Monit. 2008;30:113–116
  144. Krasinskas AM, Kreisel D, Acker MA, et al. CD3 monitoring of antithymocyte globulin therapy in thoracic organ transplantation. Transplantation. 2002;73:1339–1341
  145. Uber PA, Mehra MR, Park MH, Scott RL. Clopidogrel and rhabdomyolysis after heart transplantation. J Heart Lung Transplant. 2003;22:107–108
  146. Hmiel SP, Canter C, Shepherd R, Lassa-Claxton S, Nadler M. Limitations of cyclosporine C2 monitoring in pediatric heart transplant recipients. Pediatr Transplant. 2007;11:524–529
  147. Schubert S, bdul-Khaliq H, Lehmkuhl HB, et al. Advantages of C2 monitoring to avoid acute rejection in pediatric heart transplant recipients. J Heart Lung Transplant. 2006;25:619–625
  148. Gajarski RJ, Crowley DC, Zamberlan MC, Lake KD. Lack of correlation between MMF dose and MPA level in pediatric and young adult cardiac transplant patients: does the MPA level matter?. Am J Transplant. 2004;4:1495–1500
  149. Dipchand AI, Pietra B, McCrindle BW, Rosebrook-Bicknell HL, Boucek MM. Mycophenolic acid levels in pediatric heart transplant recipients receiving mycophenolate mofetil. J Heart Lung Transplant. 2001;20:1035–1043
  150. Halloran PF, Gourishankar S. Principles and overview of immunosuppression. In:  Norman DJ,  Laurel NJ editor. Primer on transplantation. Mt Laurel, NJ: American Society of Transplantation; 2001;p. 87–98
  151. Scheinman RI, Cogswell PC, Lofquist AK, Baldwin AS. Role of transcriptional activation of I kappa B alpha in mediation of immunosuppression by glucocorticoids. Science. 1995;270:283–286
  152. Teuteberg JJ, Shullo M, Zomak R, et al. Aggressive steroid weaning after cardiac transplantation is possible without the additional risk of significant rejection. Clin Transplant. 2008;22:730–737
  153. Taylor DO, Barr ML, Radovancevic B, et al. A randomized, multicenter comparison of tacrolimus and cyclosporine immunosuppressive regimens in cardiac transplantation: decreased hyperlipidemia and hypertension with tacrolimus. J Heart Lung Transplant. 1999;18:336–345
  154. Grimm M, Rinaldi M, Yonan NA, et al. Superior prevention of acute rejection by tacrolimus vs. cyclosporine in heart transplant recipients—a large European trial. Am J Transplant. 2006;6:1387–1397
  155. Mancini D, Pinney S, Burkhoff D, et al. Use of rapamycin slows progression of cardiac transplantation vasculopathy. Circulation. 2003;108:48–53
  156. Keogh A, Richardson M, Ruygrok P, et al. Sirolimus in de novo heart transplant recipients reduces acute rejection and prevents coronary artery disease at 2 years: a randomized clinical trial. Circulation. 2004;110:2694–2700
  157. Eisen HJ, Tuzcu EM, Dorent R, et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med. 2003;349:847–858
  158. Kobashigawa JA, Miller LW, Russell SD, et al. Tacrolimus with mycophenolate mofetil (MMF) or sirolimus vs. cyclosporine with MMF in cardiac transplant patients: 1-year report. Am J Transplant. 2006;6:1377–1386
  159. Baran DA, Zucker MJ, Arroyo LH, et al. Randomized trial of tacrolimus monotherapy: tacrolimus in combination, tacrolimus alone compared (the TICTAC trial). J Heart Lung Transplant. 2007;26:992–997
  160. Lehmkuhl H, Livi U, Arizon J, et al. Results of a 12-month, multicenter, randomized trial of everolimus with reduced-exposure cyclosporine versus mycophenolate mofetil and standard-exposure cyclosporine in de novo cardiac transplantation recipients. J Heart Lung Transplant. 2008;27(2S):S65
  161. Raichlin E, Khalpey Z, Kremers W, et al. Replacement of calcineurin-inhibitors with sirolimus as primary immunosuppression in stable cardiac transplant recipients. Transplantation. 2007;84:467–474
  162. Groetzner J, Meiser B, Landwehr P, et al. Mycophenolate mofetil and sirolimus as calcineurin inhibitor-free immunosuppression for late cardiac-transplant recipients with chronic renal failure. Transplantation. 2004;77:568–574
  163. Kobashigawa J, Miller L, Renlund D, et al. A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients (Mycophenolate Mofetil Investigators). Transplantation. 1998;66:507–515
  164. Kobashigawa JA, Tobis JM, Mentzer RM, et al. Mycophenolate mofetil reduces intimal thickness by intravascular ultrasound after heart transplant: reanalysis of the multicenter trial. Am J Transplant. 2006;6:993–997
  165. Kirk AD. Induction immunosuppression. Transplantation. 2006;82:593–602
  166. Bonnefoy-Berard N, Revillard JP. Mechanisms of immunosuppression induced by antithymocyte globulins and OKT3. J Heart Lung Transplant. 1996;15:435–442
  167. Bourdage JS, Hamlin DM. Comparative polyclonal antithymocyte globulin and antilymphocyte/antilymphoblast globulin anti-CD antigen analysis by flow cytometry. Transplantation. 1995;59:1194–1200
  168. Rebellato LM, Gross U, Verbanac KM, Thomas JM. A comprehensive definition of the major antibody specificities in polyclonal rabbit antithymocyte globulin. Transplantation. 1994;57:685–694
  169. Crespo-Leiro MG, onso-Pulpon L, Arizon JM, et al. Influence of induction therapy, immunosuppressive regimen and anti-viral prophylaxis on development of lymphomas after heart transplantation: data from the Spanish Post-Heart Transplant Tumour Registry. J Heart Lung Transplant. 2007;26:1105–1109
  170. Barr ML, Sanchez JA, Seche LA, et al. Anti-CD3 monoclonal antibody induction therapy (Immunological equivalency with triple-drug therapy in heart transplantation). Circulation. 1990;82(5 suppl):IV291–IV294
  171. Swinnen LJ, Costanzo-Nordin MR, Fisher SG, et al. Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant recipients. N Engl J Med. 1990;323:1723–1728
  172. Teuteberg J, Shullo M, Zomak R, et al. Alemtuzumab induction facilitates corticosteroid-free maintenance immunosuppression inhuman cardiac transplantation. J Heart Lung Transplant. 2008;27:S201–S202
  173. Pham SM, Jimenez J, Bednar BM, et al. Campath-1H in clinical heart transplantation. J Heart Lung Transplant. 2006;25:S228
  174. Das B, Shoemaker L, Recto M, Austin E, Dowling R. Alemtuzumab (Campath-1H) induction in a pediatric heart transplant: successful outcome and rationale for its use. J Heart Lung Transplant. 2008;27:242–244
  175. Zuckermann AO, Grimm M, Czerny M, et al. Improved long-term results with thymoglobuline induction therapy after cardiac transplantation: a comparison of two different rabbit-antithymocyte globulines. Transplantation. 2000;69:1890–1898
  176. Macdonald PS, Mundy J, Keogh AM, Chang VP, Spratt PM. A prospective randomized study of prophylactic OKT3 versus equine antithymocyte globulin after heart transplantation—increased morbidity with OKT3. Transplantation. 1993;55:110–116
  177. Goland S, Czer LS, Coleman B, et al. Induction therapy with thymoglobulin after heart transplantation: impact of therapy duration on lymphocyte depletion and recovery, rejection, and cytomegalovirus infection rates. J Heart Lung Transplant. 2008;27:1115–1121
  178. Delgado DH, Miriuka SG, Cusimano RJ, et al. Use of basiliximab and cyclosporine in heart transplant patients with pre-operative renal dysfunction. J Heart Lung Transplant. 2005;24:166–169
  179. Cantarovich M, Giannetti N, Barkun J, Cecere R. Antithymocyte globulin induction allows a prolonged delay in the initiation of cyclosporine in heart transplant patients with postoperative renal dysfunction. Transplantation. 2004;78:779–781
  180. Beniaminovitz A, Itescu S, Lietz K, et al. Prevention of rejection in cardiac transplantation by blockade of the interleukin-2 receptor with a monoclonal antibody. N Engl J Med. 2000;342:613–619
  181. Hershberger RE, Starling RC, Eisen HJ, et al. Daclizumab to prevent rejection after cardiac transplantation. N Engl J Med. 2005;352:2705–2713
  182. Mehra MR, Zucker MJ, Wagoner L, et al. A multicenter, prospective, randomized, double-blind trial of basiliximab in heart transplantation. J Heart Lung Transplant. 2005;24:1297–1304
  183. Chin C, Pittson S, Luikart H, et al. Induction therapy for pediatric and adult heart transplantation: comparison between OKT3 and daclizumab. Transplantation. 2005;80:477–481
  184. Segovia J, Rodriguez-Lambert JL, Crespo-Leiro MG, et al. A randomized multicenter comparison of basiliximab and muromonab (OKT3) in heart transplantation: SIMCOR study. Transplantation. 2006;81:1542–1548
  185. Carlsen J, Johansen M, Boesgaard S, et al. Induction therapy after cardiac transplantation: a comparison of anti-thymocyte globulin and daclizumab in the prevention of acute rejection. J Heart Lung Transplant. 2005;24:296–302
  186. Carrier M, Leblanc MH, Perrault LP, et al. Basiliximab and rabbit anti-thymocyte globulin for prophylaxis of acute rejection after heart transplantation: a non-inferiority trial. J Heart Lung Transplant. 2007;26:258–263
  187. Mattei MF, Redonnet M, Gandjbakhch I, et al. Lower risk of infectious deaths in cardiac transplant patients receiving basiliximab versus anti-thymocyte globulin as induction therapy. J Heart Lung Transplant. 2007;26:693–699
  188. Meiser B, Reichart B, Adamidis I, Uberfuhr P, Kaczmarek I. First experience with de novo calcineurin-inhibitor-free immunosuppression following cardiac transplantation. Am J Transplant. 2005;5:827–831
  189. Gonzalez-Vilchez F, de Prada JA, Exposito V, et al. Avoidance of calcineurin inhibitors with use of proliferation signal inhibitors in de novo heart transplantation with renal failure. J Heart Lung Transplant. 2008;27:1135–1141
  190. Lebeck LK, Chang L, Lopez-McCormack C, Chinnock R, Boucek M. Polyclonal antithymocyte serum: immune prophylaxis and rejection therapy in pediatric heart transplantation patients. J Heart Lung Transplant. 1993;12:S286–S292
  191. Parisi F, Danesi H, Squitieri C, Di Chiara L, Ravà L, Di Donato RM. Thymoglobuline use in pediatric heart transplantation. J Heart Lung Transplant. 2003;22:591–593
  192. Pollock-Barziv SM, lain-Rooney T, Manlhiot C, et al. Continuous infusion of thymoglobulin for induction therapy in pediatric heart transplant recipients; experience and outcomes with a novel strategy for administration. Pediatr Transplant. 2009;13:585–589
  193. Boucek RJ, Naftel D, Boucek MM, et al. Induction immunotherapy in pediatric heart transplant recipients: a multicenter study. J Heart Lung Transplant. 1999;18:460–469
  194. Kobashigawa JA, Katznelson S, Laks H, et al. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med. 1995;333:621–627
  195. Wenke K, Meiser B, Thiery J, et al. Simvastatin reduces graft vessel disease and mortality after heart transplantation: a four-year randomized trial. Circulation. 1997;96:1398–1402
  196. Weitz-Schmidt G, Welzenbach K, Brinkmann V, et al. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat Med. 2001;7:687–692
  197. Weis M, Pehlivanli S, Meiser BM, von SW. Simvastatin treatment is associated with improvement in coronary endothelial function and decreased cytokine activation in patients after heart transplantation. J Am Coll Cardiol. 2001;38:814–818
  198. Kobashigawa JA, Moriguchi JD, Laks H, et al. Ten-year follow-up of a randomized trial of pravastatin in heart transplant patients. J Heart Lung Transplant. 2005;24:1736–1740
  199. Wenke K, Meiser B, Thiery J, et al. Simvastatin initiated early after heart transplantation: 8-year prospective experience. Circulation. 2003;107:93–97
  200. Mehra MR, Uber PA, Vivekananthan K, et al. Comparative beneficial effects of simvastatin and pravastatin on cardiac allograft rejection and survival. J Am Coll Cardiol. 2002;40:1609–1614
  201. Magnani G, Carinci V, Magelli C, et al. Role of statins in the management of dyslipidemia after cardiac transplant: randomized controlled trial comparing the efficacy and the safety of atorvastatin with pravastatin. J Heart Lung Transplant. 2000;19:710–715
  202. Samman A, Imai C, Straatman L, et al. Safety and efficacy of rosuvastatin therapy for the prevention of hyperlipidemia in adult cardiac transplant recipients. J Heart Lung Transplant. 2005;24:1008–1013
  203. Penson MG, Fricker FJ, Thompson JR, et al. Safety and efficacy of pravastatin therapy for the prevention of hyperlipidemia in pediatric and adolescent cardiac transplant recipients. J Heart Lung Transplant. 2001;20:611–618
  204. Chin C, Gamberg P, Miller J, Luikart H, Bernstein D. Efficacy and safety of atorvastatin after pediatric heart transplantation. J Heart Lung Transplant. 2002;21:1213–1217
  205. Hedman M, Neuvonen PJ, Neuvonen M, Holmberg C, Antikainen M. Pharmacokinetics and pharmacodynamics of pravastatin in pediatric and adolescent cardiac transplant recipients on a regimen of triple immunosuppression. Clin Pharmacol Ther. 2004;75:101–109
  206. Mahle WT, Vincent RN, Berg AM, Kanter KR. Pravastatin therapy is associated with reduction in coronary allograft vasculopathy in pediatric heart transplantation. J Heart Lung Transplant. 2005;24:63–66
  207. Chin C, Lukito SS, Shek J, Bernstein D, Perry SB. Prevention of pediatric graft coronary artery disease: atorvastatin. Pediatr Transplant. 2008;12:442–446
  208. Zuppan CW, Wells LM, Kerstetter JC, et al. Cause of death in pediatric and infant heart transplant recipients: review of a 20-year, single-institution cohort. J Heart Lung Transplant. 2009;28:579–584
  209. Reichart B, Meiser B, Vigano M, et al. European multicenter tacrolimus heart pilot study: three year follow-up. J Heart Lung Transplant. 2001;20:249–250
  210. Bilchick KC, Henrikson CA, Skojec D, Kasper EK, Blumenthal RS. Treatment of hyperlipidemia in cardiac transplant recipients. Am Heart J. 2004;148:200–210
  211. Heublein B, Wahlers T, Haverich A. Pulsed steroids for treatment of cardiac rejection after transplantation (What dosage is necessary?). Circulation. 1989;80:III97–III99
  212. Lonquist JL, Radovancevic B, Vega JD, et al. Reevaluation of steroid tapering after steroid pulse therapy for heart rejection. J Heart Lung Transplant. 1992;11:913–919
  213. Haverty TP, Sanders M, Sheahan M. OKT3 treatment of cardiac allograft rejection. J Heart Lung Transplant. 1993;12:591–598
  214. Woodside KJ, Lick SD. Alemtuzumab (Campath 1H) as successful salvage therapy for recurrent steroid-resistant heart transplant rejection. J Heart Lung Transplant. 2007;26:750–752
  215. Onsager DR, Canver CC, Jahania MS, et al. Efficacy of tacrolimus in the treatment of refractory rejection in heart and lung transplant recipients. J Heart Lung Transplant. 1999;18:448–455
  216. Chan MC, Kwok BW, Shiba N, et al. Conversion of cyclosporine to tacrolimus for refractory or persistent myocardial rejection. Transplant Proc. 2002;34:1850–1852
  217. Yamani MH, Starling RC, Pelegrin D, et al. Efficacy of tacrolimus in patients with steroid-resistant cardiac allograft cellular rejection. J Heart Lung Transplant. 2000;19:337–342
  218. Costanzo-Nordin MR, McManus BM, Wilson JE, et al. Efficacy of photopheresis in the rescue therapy of acute cellular rejection in human heart allografts: a preliminary clinical and immunopathologic report. Transplant Proc. 1993;25:881–883
  219. Keogh AM, Arnold RH, Macdonald PS, et al. A randomized trial of tacrolimus (FK506) versus total lymphoid irradiation for the control of repetitive rejection after cardiac transplantation. J Heart Lung Transplant. 2001;20:1331–1334
  220. Atluri P, Hiesinger W, Gorman RC, et al. Cardiac retransplantation is an efficacious therapy for primary cardiac allograft failure. J Cardiothorac Surg. 2008;3:26
  221. Grauhan O, Knosalla C, Ewert R, et al. Plasmapheresis and cyclophosphamide in the treatment of humoral rejection after heart transplantation. J Heart Lung Transplant. 2001;20:316–321
  222. Kaczmarek I, Deutsch MA, Sadoni S, et al. Successful management of antibody-mediated cardiac allograft rejection with combined immunoadsorption and anti-CD20 monoclonal antibody treatment: case report and literature review. J Heart Lung Transplant. 2007;26:511–515
  223. Garrett HE, Duvall-Seaman D, Helsley B, Groshart K. Treatment of vascular rejection with rituximab in cardiac transplantation. J Heart Lung Transplant. 2005;24:1337–1342
  224. Rose ML, Smith J, Dureau G, Keogh A, Kobashigowa J. Mycophenolate mofetil decreases antibody production after cardiac transplantation. J Heart Lung Transplant. 2002;21:282–285
  225. Itescu S, Burke E, Lietz K, et al. Intravenous pulse administration of cyclophosphamide is an effective and safe treatment for sensitized cardiac allograft recipients. Circulation. 2002;105:1214–1219
  226. Leech SH, Lopez-Cepero M, LeFor WM, et al. Management of the sensitized cardiac recipient: the use of plasmapheresis and intravenous immunoglobulin. Clin Transplant. 2006;20:476–484
  227. Kfoury AG, Hammond ME, Snow GL, et al. Early screening for antibody-mediated rejection in heart transplant recipients. J Heart Lung Transplant. 2007;26:1264–1269
  228. Michaels PJ, Espejo ML, Kobashigawa J, et al. Humoral rejection in cardiac transplantation: risk factors, hemodynamic consequences and relationship to transplant coronary artery disease. J Heart Lung Transplant. 2003;22:58–69
  229. Miller LW, Wesp A, Jennison SH, et al. Vascular rejection in heart transplant recipients. J Heart Lung Transplant. 1993;12:S147–S152
  230. Brunner-La Rocca HP, Schneider J, Kunzli A, Turina M, Kiowski W. Cardiac allograft rejection late after transplantation is a risk factor for graft coronary artery disease. Transplantation. 1998;65:538–543
  231. Klingenberg R, Koch A, Schnabel PA, et al. Allograft rejection of ISHLT grade >/=3A occurring late after heart transplantation—a distinct entity?. J Heart Lung Transplant. 2003;22:1005–1013
  232. Esmore DS, Spratt PM, Keogh AM, Chang VP. Cyclosporine and azathioprine immunosuppression without maintenance steroids: a prospective randomized trial. J Heart Transplant. 1989;8:194–199
  233. Miller LW, Wolford T, McBride LR, Peigh P, Pennington DG. Successful withdrawal of corticosteroids in heart transplantation. J Heart Lung Transplant. 1992;11:431–434
  234. Yamani MH, Taylor DO, Czerr J, et al. Thymoglobulin induction and steroid avoidance in cardiac transplantation: results of a prospective, randomized, controlled study. Clin Transplant. 2008;22:76–81
  235. Angermann CE, Stork S, Costard-Jackle A, et al. Reduction of cyclosporine after introduction of mycophenolate mofetil improves chronic renal dysfunction in heart transplant recipients—the IMPROVED multi-centre study. Eur Heart J. 2004;25:1626–1634
  236. Rice JE, Shipp AT, Carlin JB, Vidmar SI, Weintraub RG. Late reduction in cyclosporine dosage does not improve renal function in pediatric heart transplant recipients. J Heart Lung Transplant. 2002;21:1109–1112
  237. Trosch F, Rothenburger M, Schneider M, et al. First experience with rapamycin-based immunosuppression to improve kidney function after heart transplantation. Thorac Cardiovasc Surg. 2004;52:163–168
  238. Hamour IM, Lyster HS, Burke MM, Rose ML, Banner NR. Mycophenolate mofetil may allow cyclosporine and steroid sparing in de novo heart transplant patients. Transplantation. 2007;83:570–576
  239. Gustafsson F, Ross HJ, Delgado MS, Bernabeo G, Delgado DH. Sirolimus-based immunosuppression after cardiac transplantation: predictors of recovery from calcineurin inhibitor-induced renal dysfunction. J Heart Lung Transplant. 2007;26:998–1003
  240. Raichlin E, Bae JH, Khalpey Z, et al. Conversion to sirolimus as primary immunosuppression attenuates the progression of allograft vasculopathy after cardiac transplantation. Circulation. 2007;116:2726–2733
  241. Leonard H, Hornung T, Parry G, Dark JH. Pediatric cardiac transplant: results using a steroid-free maintenance regimen. Pediatr Transplant. 2003;7:59–63
  242. Schachter AD, Meyers KE, Spaneas LD, et al. Short sirolimus half-life in pediatric renal transplant recipients on a calcineurin inhibitor-free protocol. Pediatr Transplant. 2004;8:171–177
  243. van de Beek D, Kremers W, Daly RC, et al. Effect of neurologic complications on outcome after heart transplant. Arch Neurol. 2008;65:226–231
  244. Zierer A, Melby SJ, Voeller RK, et al. Significance of neurologic complications in the modern era of cardiac transplantation. Ann Thorac Surg. 2007;83:1684–1690
  245. Mayer TO, Biller J, O'Donnell J, Meschia JF, Sokol DK. Contrasting the neurologic complications of cardiac transplantation in adults and children. J Child Neurol. 2002;17:195–199
  246. Mateen FJ, van de BD, Kremers WK, et al. Neuromuscular diseases after cardiac transplantation. J Heart Lung Transplant. 2009;28:226–230
  247. Kapadia SR, Nissen SE, Ziada KM, et al. Development of transplantation vasculopathy and progression of donor-transmitted atherosclerosis: comparison by serial intravascular ultrasound imaging. Circulation. 1998;98:2672–2678
  248. St Goar FG, Pinto FJ, Alderman EL, et al. Intracoronary ultrasound in cardiac transplant recipients (In vivo evidence of “angiographically silent” intimal thickening). Circulation. 1992;85:979–987
  249. Kobashigawa JA, Tobis JM, Starling RC, et al. Multicenter intravascular ultrasound validation study among heart transplant recipients: outcomes after five years. J Am Coll Cardiol. 2005;45:1532–1537
  250. Nicolas RT, Kort HW, Balzer DT, et al. Surveillance for transplant coronary artery disease in infant, child and adolescent heart transplant recipients: an intravascular ultrasound study. J Heart Lung Transplant. 2006;25:921–927
  251. Kuhn MA, Jutzy KR, Deming DD, et al. The medium-term findings in coronary arteries by intravascular ultrasound in infants and children after heart transplantation. J Am Coll Cardiol. 2000;36:250–254
  252. Farzaneh-Far A. Electron-beam computed tomography in the assessment of coronary artery disease after heart transplantation. Circulation. 2001;103:E60
  253. Pichler P, Loewe C, Roedler S, et al. Detection of high-grade stenoses with multislice computed tomography in heart transplant patients. J Heart Lung Transplant. 2008;27:310–316
  254. Dipchand AI, Bharat W, Manlhiot C, et al. A prospective study of dobutamine stress echocardiography for the assessment of cardiac allograft vasculopathy in pediatric heart transplant recipients. Pediatr Transplant. 2008;12:570–576
  255. Hacker M, Hoyer HX, Uebleis C, et al. Quantitative assessment of cardiac allograft vasculopathy by real-time myocardial contrast echocardiography: a comparison with conventional echocardiographic analyses and [Tc99m]-sestamibi SPECT. Eur J Echocardiogr. 2008;9:494–500
  256. Eroglu E, D'hooge J, Sutherland GR, et al. Quantitative dobutamine stress echocardiography for the early detection of cardiac allograft vasculopathy in heart transplant recipients. Heart. 2008;94:e3
  257. Mehra MR. Contemporary concepts in prevention and treatment of cardiac allograft vasculopathy. Am J Transplant. 2006;6:1248–1256
  258. Botha P, Peaston R, White K, et al. Smoking after cardiac transplantation. Am J Transplant. 2008;8:866–871
  259. McDonald K, Rector TS, Braulin EA, Kubo SH, Olivari MT. Association of coronary artery disease in cardiac transplant recipients with cytomegalovirus infection. Am J Cardiol. 1989;64:359–362
  260. Simmonds J, Fenton M, Dewar C, et al. Endothelial dysfunction and cytomegalovirus replication in pediatric heart transplantation. Circulation. 2008;117:2657–2661
  261. Hussain T, Burch M, Fenton MJ, et al. Positive pretransplantation cytomegalovirus serology is a risk factor for cardiac allograft vasculopathy in children. Circulation. 2007;115:1798–1805
  262. Kato T, Chan MC, Gao SZ, et al. Glucose intolerance, as reflected by hemoglobin A1c level, is associated with the incidence and severity of transplant coronary artery disease. J Am Coll Cardiol. 2004;43:1034–1041
  263. Schroeder JS, Gao SZ, Alderman EL, et al. A preliminary study of diltiazem in the prevention of coronary artery disease in heart-transplant recipients. N Engl J Med. 1993;328:164–170
  264. Erinc K, Yamani MH, Starling RC, et al. The effect of combined Angiotensin-converting enzyme inhibition and calcium antagonism on allograft coronary vasculopathy validated by intravascular ultrasound. J Heart Lung Transplant. 2005;24:1033–1038
  265. Halle AA, DiSciascio G, Massin EK, et al. Coronary angioplasty, atherectomy and bypass surgery in cardiac transplant recipients. J Am Coll Cardiol. 1995;26:120–128
  266. Aqel RA, Wells BJ, Hage FG, et al. Re-stenosis after drug-eluting stents in cardiac allograft vasculopathy. J Heart Lung Transplant. 2008;27:610–615
  267. Radovancevic B, McGiffin DC, Kobashigawa JA, et al. Retransplantation in 7,290 primary transplant patients: a 10-year multi-institutional study. J Heart Lung Transplant. 2003;22:862–868
  268. Crespo-Leiro MG, onso-Pulpon L, Vazquez de Prada JA, et al. Malignancy after heart transplantation: incidence, prognosis and risk factors. Am J Transplant. 2008;8:1031–1039
  269. Webber SA, Naftel DC, Fricker FJ, et al. Lymphoproliferative disorders after paediatric heart transplantation: a multi-institutional study. Lancet. 2006;367:233–239
  270. O'Neill JO, Edwards LB, Taylor DO. Mycophenolate mofetil and risk of developing malignancy after orthotopic heart transplantation: analysis of the transplant registry of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant. 2006;25:1186–1191
  271. Valantine H. Is there a role for proliferation signal/mTOR inhibitors in the prevention and treatment of de novo malignancies after heart transplantation? (Lessons learned from renal transplantation and oncology). J Heart Lung Transplant. 2007;26:557–564
  272. Senzolo M, Ferronato C, Burra P. Neurologic complications after solid organ transplantation. Transpl Int. 2009;22:269–278
  273. Alonso EM. Long-term renal function in pediatric liver and heart recipients. Pediatr Transplant. 2004;8:381–385
  274. Lee CK, Christensen LL, Magee JC, et al. Pre-transplant risk factors for chronic renal dysfunction after pediatric heart transplantation: a 10-year national cohort study. J Heart Lung Transplant. 2007;26:458–465
  275. Wilkinson AH, Cohen DJ. Renal failure in the recipients of nonrenal solid organ transplants. J Am Soc Nephrol. 1999;10:1136–1144
  276. Ojo AO. Renal disease in recipients of nonrenal solid organ transplantation. Semin Nephrol. 2007;27:498–507
  277. Bloom RD, Doyle AM. Kidney disease after heart and lung transplantation. Am J Transplant. 2006;6:671–679
  278. Myers BD, Newton L. Cyclosporine-induced chronic nephropathy: an obliterative microvascular renal injury. J Am Soc Nephrol. 1991;2(2 suppl 1):S45–S52
  279. Kopp JB, Klotman PE. Cellular and molecular mechanisms of cyclosporin nephrotoxicity. J Am Soc Nephrol. 1990;1:162–179
  280. Schmid H, Burg M, Kretzler M, et al. BK virus associated nephropathy in native kidneys of a heart allograft recipient. Am J Transplant. 2005;5:1562–1568
  281. Randhawa P, Brennan DC. BK virus infection in transplant recipients: an overview and update. Am J Transplant. 2006;6:2000–2005
  282. Gleissner CA, Murat A, Schafer S, et al. Reduced hemoglobin after heart transplantation is no independent risk factor for survival but is associated closely with impaired renal function. Transplantation. 2004;77:710–717
  283. Marchetti P. New-onset diabetes after transplantation. J Heart Lung Transplant. 2004;23(5 suppl):S194–S201
  284. Bloom RD, Crutchlow MF. Transplant-associated hyperglycemia. Transplant Rev (Orlando). 2008;22:39–51
  285. Hathout EH, Chinnock RE, Johnston JK, et al. Pediatric post-transplant diabetes: data from a large cohort of pediatric heart-transplant recipients. Am J Transplant. 2003;3:994–998
  286. Pham PT, Pham PC, Lipshutz GS, Wilkinson AH. New onset diabetes mellitus after solid organ transplantation. Endocrinol Metab Clin North Am. 2007;36:873–890
  287. Davidson J, Wilkinson A, Dantal J, et al. New-onset diabetes after transplantation: 2003 International consensus guidelines. Proceedings of an international expert panel meeting. Barcelona, Spain, 19 February 2003 Transplantation. 2003;75(10 suppl):SS3–SS24
  288. Wilkinson A, Davidson J, Dotta F, et al. Guidelines for the treatment and management of new-onset diabetes after transplantation. Clin Transplant. 2005;19:291–298
  289. Kuppahally S, Al-Khaldi A, Weisshaar D, et al. Wound healing complications with de novo sirolimus versus mycophenolate mofetil-based regimen in cardiac transplant recipients. Am J Transplant. 2006;6:986–992
  290. Diaz B, Gonzalez VF, Almenar L, et al. Gastrointestinal complications in heart transplant patients: MITOS study. Transplant Proc. 2007;39:2397–2400
  291. Kobashigawa JA, Renlund DG, Gerosa G, et al. Similar efficacy and safety of enteric-coated mycophenolate sodium (EC-MPS, myfortic) compared with mycophenolate mofetil (MMF) in de novo heart transplant recipients: results of a 12-month, single-blind, randomized, parallel-group, multicenter study. J Heart Lung Transplant. 2006;25:935–941
  292. Galiwango PJ, Delgado DH, Yan R, et al. Mycophenolate mofetil dose reduction for gastrointestinal intolerance is associated with increased rates of rejection in heart transplant patients. J Heart Lung Transplant. 2008;27:72–77
  293. Felkel TO, Smith AL, Reichenspurner HC, et al. Survival and incidence of acute rejection in heart transplant recipients undergoing successful withdrawal from steroid therapy. J Heart Lung Transplant. 2002;21:530–539
  294. Saeed SA, Integlia MJ, Pleskow RG, et al. Tacrolimus-associated eosinophilic gastroenterocolitis in pediatric liver transplant recipients: role of potential food allergies in pathogenesis. Pediatr Transplant. 2006;10:730–735
  295. Woo SB, Treister N. Ciclosporin-induced fibrovascular polyps vs. bacillary angiomatosis. Br J Dermatol. 2008;158:652–653
  296. De Iudicibus S, Castronovo G, Gigante A, et al. Role of MDR1 gene polymorphisms in gingival overgrowth induced by cyclosporine in transplant patients. J Periodontal Res. 2008;43:665–672
  297. Ozdemir O, rrey-Mensah A, Sorensen RU. Development of multiple food allergies in children taking tacrolimus after heart and liver transplantation. Pediatr Transplant. 2006;10:380–383
  298. Fuchs U, Zittermann A, Berthold HK, et al. Immunosuppressive therapy with everolimus can be associated with potentially life-threatening lingual angioedema. Transplantation. 2005;79:981–983
  299. Exposito V, de Prada JA, Gomez-Roman JJ, et al. Everolimus-related pulmonary toxicity in heart transplant recipients. J Heart Lung Transplant. 2008;27:797–800
  300. Lindenfeld JA, Simon SF, Zamora MR, et al. BOOP is common in cardiac transplant recipients switched from a calcineurin inhibitor to sirolimus. Am J Transplant. 2005;5:1392–1396
  301. Lubbe J, Sorg O, Male PJ, Saurat JH, Masouye I. Sirolimus-induced inflammatory papules with acquired reactive perforating collagenosis. Dermatology. 2008;216:239–242
  302. Deutsch MA, Kaczmarek I, Huber S, et al. Sirolimus-associated infertility: case report and literature review of possible mechanisms. Am J Transplant. 2007;7:2414–2421
  303. Raza S, Ullah K, Ahmed P, et al. Cyclosporine induced neurotoxicity in a stem cell transplant recipient. J Pak Med Assoc. 2007;57:611–613
  304. Morelli N, Mancuso M, Cafforio G, Gori S, Murri L. Reversible brachial diplegia in a case treated with cyclosporine. Neurology. 2007;69:220
  305. Sevmis S, Karakayali H, Emiroglu R, Akkoc H, Haberal M. Tacrolimus-related seizure in the early postoperative period after liver transplantation. Transplant Proc. 2007;39:1211–1213
  306. Kaczmarek I, Schmauss D, Sodian R, et al. Late-onset tacrolimus-associated cerebellar atrophia in a heart transplant recipient. J Heart Lung Transplant. 2007;26:89–92
  307. Norman K, Bonatti H, Dickson RC, randa-Michel J. Sudden hearing loss associated with tacrolimus in a liver transplant recipient. Transpl Int. 2006;19:601–603
  308. Frantzeskaki F, Paramythiotou E, Papathanasiou M, et al. Posterior reversible encephalopathy syndrome in an intensive care unit patient receiving tacrolimus. Acta Anaesthesiol Scand. 2008;52:1177
  309. De Weerdt A, Claeys KG, De JP, et al. Tacrolimus-related polyneuropathy: case report and review of the literature. Clin Neurol Neurosurg. 2008;110:291–294
  310. Miyagi S, Sekiguchi S, Kawagishi N, et al. Parkinsonism during cyclosporine treatment in liver transplantation: an unusual case report. Transplant Proc. 2008;40:2823–2824
  311. Up to Date Online. 2010;http://www.uptodateonline.com
  312. Lipshutz GS, Pham PC, Ghobrial MR, et al. Thrombotic microangiopathy following pancreas after kidney transplants. Clin Transplant. 2008;22:236–241
  313. Tricot L, Lebbe C, Pillebout E, et al. Tacrolimus-induced alopecia in female kidney-pancreas transplant recipients. Transplantation. 2005;80:1546–1549
  314. Kim PT, Davis JE, Erb SR, Yoshida EM, Steinbrecher UP. Colonic malakoplakia in a liver transplant recipient. Can J Gastroenterol. 2007;21:753–755
  315. Taniai N, Akimaru K, Ishikawa Y, et al. Hepatotoxicity caused by both tacrolimus and cyclosporine after living donor liver transplantation. J Nippon Med Sch. 2008;75:187–191
  316. Shah S, Budev M, Blazey H, Fairbanks K, Mehta A. Hepatic veno-occlusive disease due to tacrolimus in a single-lung transplant patient. Eur Respir J. 2006;27:1066–1068
  317. Blanchard SS, Gerrek M, Czinn S, et al. Food protein sensitivity with partial villous atrophy after pediatric liver transplantation with tacrolimus immunosuppression. Pediatr Transplant. 2006;10:529–532
  318. McCalmont V, Bennett K. Progressive multifocal leukoencephalopathy: a case study. Prog Transplant. 2007;17:157–160
  319. Papali A, Giannetti N, Cantarovich M. Unilateral upper extremity edema associated with sirolimus in a heart transplant patient. Transplantation. 2007;83:240
  320. van Onna M, Geerts A, Van VH, et al. One-sided limb lymphedema in a liver transplant recipient receiving sirolimus. Acta Gastroenterol Belg. 2007;70:357–359
  321. Garcia-Luque A, Cordero E, Torello J, et al. Sirolimus-associated pneumonitis in heart transplant recipients. Ann Pharmacother. 2008;42:1143–1145
  322. Perez MJ, Martin RO, Garcia DM, et al. Interstitial pneumonitis associated with sirolimus in liver transplantation: a case report. Transplant Proc. 2007;39:3498–3499
  323. Tracey C, Hawley C, Griffin AD, Strutton G, Lynch S. Generalized, pruritic, ulcerating maculopapular rash necessitating cessation of sirolimus in a liver transplantation patient. Liver Transpl. 2005;11:987–989
  324. Zakliczynski M, Nozynski J, Kocher A, et al. Surgical wound-healing complications in heart transplant recipients treated with rapamycin. Wound Repair Regen. 2007;15:316–321
  325. Neff GW, Ruiz P, Madariaga JR, et al. Sirolimus-associated hepatotoxicity in liver transplantation. Ann Pharmacother. 2004;38:1593–1596
  326. Smith AD, Bai D, Marroquin CE, et al. Gastrointestinal hemorrhage due to complicated gastroduodenal ulcer disease in liver transplant patients taking sirolimus. Clin Transplant. 2005;19:250–254
  327. Schacherer D, Zeitoun M, Buttner R, et al. Sirolimus-induced drug fever and ciclosporin-induced leukencephalopathia with seizures in one liver transplant recipient. World J Gastroenterol. 2007;13:6090–6093
  328. Shipkova M, Armstrong VW, Oellerich M, Wieland E. Mycophenolate mofetil in organ transplantation: focus on metabolism, safety and tolerability. Expert Opin Drug Metab Toxicol. 2005;1:505–526
  329. Eisen HJ, Kobashigawa J, Keogh A, et al. Three-year results of a randomized, double-blind, controlled trial of mycophenolate mofetil versus azathioprine in cardiac transplant recipients. J Heart Lung Transplant. 2005;24:517–525
  330. Kapetanakis EI, Antonopoulos AS, Antoniou TA, et al. Effect of long-term calcitonin administration on steroid-induced osteoporosis after cardiac transplantation. J Heart Lung Transplant. 2005;24:526–532
  331. Yong G, Hayes H, O'Driscoll G. Strategy of aggressive steroid weaning and routine alendronate therapy to reduce bone loss after cardiac transplantation. Transplant Proc. 2007;39:3340–3343
  332. Shane E, Rivas M, McMahon DJ, et al. Bone loss and turnover after cardiac transplantation. J Clin Endocrinol Metab. 1997;82:1497–1506
  333. Cremer J, Struber M, Wagenbreth I, et al. Progression of steroid-associated osteoporosis after heart transplantation. Ann Thorac Surg. 1999;67:130–133
  334. Lindenfeld J, Page RL, Zolty R, et al. Drug therapy in the heart transplant recipient: part III: common medical problems. Circulation. 2005;111:113–117
  335. Sanchez-Lazaro IJ, Martinez-Dolz L, menar-Bonet L, et al. Predictor factors for the development of arterial hypertension following heart transplantation. Clin Transplant. 2008;22:760–764
  336. Klinge A, Allen J, Murray A, O'Sullivan J. Increased pulse wave velocity and blood pressure in children who have undergone cardiac transplantation. J Heart Lung Transplant. 2009;28:21–25
  337. Walker AH, Locke TJ, Braidley PC, Al-Mohammed A. The importance of 24 hour ambulatory blood pressure monitoring after thoracic organ transplantation. J Heart Lung Transplant. 2005;24:1770–1773
  338. Roche SL, Kaufmann J, Dipchand AI, Kantor PF. Hypertension after pediatric heart transplantation is primarily associated with immunosuppressive regimen. J Heart Lung Transplant. 2008;27:501–507
  339. Brozena SC, Johnson MR, Ventura H, et al. Effectiveness and safety of diltiazem or lisinopril in treatment of hypertension after heart transplantation (Results of a prospective, randomized multicenter trail). J Am Coll Cardiol. 1996;27:1707–1712
  340. Mathias HC, Ozalp F, Will MB, et al. A randomized, controlled trial of C0- Vs C2-guided therapeutic drug monitoring of cyclosporine in stable heart transplant patients. J Heart Lung Transplant. 2005;24:2137–2143
  341. Canter CE, Moorhead S, Saffitz JE, Huddleston CB, Spray TL. Steroid withdrawal in the pediatric heart transplant recipient initially treated with triple immunosuppression. J Heart Lung Transplant. 1994;13:74–79
  342. Lee AH, Mull RL, Keenan GF, et al. Osteoporosis and bone morbidity in cardiac transplant recipients. Am J Med. 1994;96:35–41
  343. Pisani B, Mullen GM. Prevention of osteoporosis in cardiac transplant recipients. Curr Opin Cardiol. 2002;17:160–164
  344. Guo CY, Johnson A, Locke TJ, Eastell R. Mechanisms of bone loss after cardiac transplantation. Bone. 1998;22:267–271
  345. Shane E, Addesso V, Namerow PB, et al. Alendronate versus calcitriol for the prevention of bone loss after cardiac transplantation. N Engl J Med. 2004;350:767–776
  346. Leidig-Bruckner G, Hosch S, Dodidou P, et al. Frequency and predictors of osteoporotic fractures after cardiac or liver transplantation: a follow-up study. Lancet. 2001;357:342–347
  347. Braith RW, Magyari PM, Fulton MN, et al. Resistance exercise training and alendronate reverse glucocorticoid-induced osteoporosis in heart transplant recipients. J Heart Lung Transplant. 2003;22:1082–1090
  348. Braith RW, Magyari PM, Fulton MN, et al. Comparison of calcitonin versus calcitonin + resistance exercise as prophylaxis for osteoporosis in heart transplant recipients. Transplantation. 2006;81:1191–1195
  349. Van Cleemput J, Daenen W, Geusens P, et al. Prevention of bone loss in cardiac transplant recipients (A comparison of biphosphonates and vitamin D). Transplantation. 1996;61:1495–1499
  350. Cohen A, Addesso V, McMahon DJ, et al. Discontinuing antiresorptive therapy one year after cardiac transplantation: effect on bone density and bone turnover. Transplantation. 2006;81:686–691
  351. Dodidou P, Bruckner T, Hosch S, et al. Better late than never? (Experience with intravenous pamidronate treatment in patients with low bone mass or fractures following cardiac or liver transplantation). Osteoporos Int. 2003;14:82–89
  352. Coscia LA, Constantinescu S, Moritz MJ, et al. Report from the National Transplantation Pregnancy Registry (NTPR): outcomes of pregnancy after transplantation. Clin Transpl. 2007;29–42
  353. Sibanda N, Briggs JD, Davison JM, Johnson RJ, Rudge CJ. Pregnancy after organ transplantation: a report from the UK Transplant pregnancy registry. Transplantation. 2007;83:1301–1307
  354. Transfer of drugs and other chemicals into human milk. Pediatrics. 2001;108:776–789
  355. Estes CM, Westhoff C. Contraception for the transplant patient. Semin Perinatol. 2007;31:372–377
  356. Sucato GS, Murray PJ. Gynecologic health care for the adolescent solid organ transplant recipient. Pediatr Transplant. 2005;9:346–356
  357. McKay DB, Josephson MA, Armenti VT, et al. Reproduction and transplantation: report on the AST Consensus Conference on Reproductive Issues and Transplantation. Am J Transplant. 2005;5:1592–1599
  358. Schofield RS, Edwards DG, Schuler BT, et al. Vascular effects of sildenafil in hypertensive cardiac transplant recipients. Am J Hypertens. 2003;16:874–877
  359. Marconi C, Marzorati M. Exercise after heart transplantation. Eur J Appl Physiol. 2003;90:250–259
  360. Biring MS, Fournier M, Ross DJ, Lewis MI. Cellular adaptations of skeletal muscles to cyclosporine. J Appl Physiol. 1998;84:1967–1975
  361. Niset G, Hermans L, Depelchin P. Exercise and heart transplantation (A review). Sports Med. 1991;12:359–379
  362. Keteyian S, Shepard R, Ehrman J, et al. Cardiovascular responses of heart transplant patients to exercise training. J Appl Physiol. 1991;70:2627–2631
  363. Kobashigawa JA, Leaf DA, Lee N, et al. A controlled trial of exercise rehabilitation after heart transplantation. N Engl J Med. 1999;340:272–277
  364. Braith RW, Schofield RS, Hill JA, Casey DP, Pierce GL. Exercise training attenuates progressive decline in brachial artery reactivity in heart transplant recipients. J Heart Lung Transplant. 2008;27:52–59
  365. Pierce GL, Schofield RS, Casey DP, et al. Effects of exercise training on forearm and calf vasodilation and proinflammatory markers in recent heart transplant recipients: a pilot study. Eur J Cardiovasc Prev Rehabil. 2008;15:10–18
  366. Haykowsky M, Taylor D, Kim D, Tymchak W. Exercise training improves aerobic capacity and skeletal muscle function in heart transplant recipients. Am J Transplant. 2009;9:734–739
  367. Braith RW, Welsch MA, Mills RM, Keller JW, Pollock ML. Resistance exercise prevents glucocorticoid-induced myopathy in heart transplant recipients. Med Sci Sports Exerc. 1998;30:483–489
  368. Patel JN, Kavey RE, Pophal SG, et al. Improved exercise performance in pediatric heart transplant recipients after home exercise training. Pediatr Transplant. 2008;12:336–340
  369. Blasco LM, Parameshwar J, Vuylsteke A. Anaesthesia for noncardiac surgery in the heart transplant recipient. Curr Opin Anaesthesiol. 2009;22:109–113
  370. Kavanagh T, Yacoub MH, Kennedy J, Austin PC. Return to work after heart transplantation: 12-year follow-up. J Heart Lung Transplant. 1999;18:846–851
  371. Paris W, Woodbury A, Thompson S, et al. Social rehabilitation and return to work after cardiac transplantation—a multicenter survey. Transplantation. 1992;53:433–438
  372. White-Williams C, Jalowiec A, Grady K. Who returns to work after heart transplantation?. J Heart Lung Transplant. 2005;24:2255–2261
  373. Tjang YS, Tenderich G, Hornik L, Korfer R. Cardiac retransplantation in adults: an evidence-based systematic review. Thorac Cardiovasc Surg. 2008;56:323–327
  374. Shuhaiber JH, Kim JB, Hur K, et al. Comparison of survival in primary and repeat heart transplantation from 1987 through 2004 in the United States. Ann Thorac Surg. 2007;83:2135–2141
  375. Chin C, Naftel D, Pahl E, et al. Cardiac re-transplantation in pediatrics: a multi-institutional study. J Heart Lung Transplant. 2006;25:1420–1424
  376. American Transplant Society. When to contact the transplant center: AST guidelines for non-transplant physicians caring for heart and/or lung transplant recipients. 2010;http://www.a-s-t.org/index2.cfm?Section=non_transp_phys
  377. Fusar-Poli P, Picchioni M, Martinelli V, et al. Anti-depressive therapies after heart transplantation. J Heart Lung Transplant. 2006;25:785–793
  378. De Bleser L, Matteson M, Dobbels F, Russell C, De GS. Interventions to improve medication-adherence after transplantation: a systematic review. Transpl Int. 2009;22:780–797
  379. Dew MA, DiMartini AF, De Vito DA, et al. Rates and risk factors for nonadherence to the medical regimen after adult solid organ transplantation. Transplantation. 2007;83:858–873
  380. Havik OE, Sivertsen B, Relbo A, et al. Depressive symptoms and all-cause mortality after heart transplantation. Transplantation. 2007;84:97–103
  381. Lawrence K, Stilley CS, Olshansky E, Bender A, Webber SA. Further exploration: maturity and adherence in adolescent and young adult heart transplant recipients. Prog Transplant. 2008;18:50–54
  382. Szepietowski JC, Reich A, Nowicka D, Weglowska J, Szepietowski T. Sun protection in renal transplant recipients: urgent need for education. Dermatology. 2005;211:93–97
  383. Wray J, Waters S, Radley-Smith R, Sensky T. Adherence in adolescents and young adults following heart or heart-lung transplantation. Pediatr Transplant. 2006;10:694–700
  384. Dobbels F, Van Damme-Lombaert R, Vanhaecke J, De GS. Growing pains: non-adherence with the immunosuppressive regimen in adolescent transplant recipients. Pediatr Transplant. 2005;9:381–390
  385. Keith DS, Cantarovich M, Paraskevas S, Tchervenkov J. Recipient age and risk of chronic allograft nephropathy in primary deceased donor kidney transplant. Transpl Int. 2006;19:649–656
  386. Rosen DS, Blum RW, Britto M, Sawyer SM, Siegel DM. Transition to adult health care for adolescents and young adults with chronic conditions: position paper of the Society for Adolescent Medicine. J Adolesc Health. 2003;33:309–311
  387. Williams MJ, Lee MY, DiSalvo TG, et al. Biopsy-induced flail tricuspid leaflet and tricuspid regurgitation following orthotopic cardiac transplantation. Am J Cardiol. 1996;77:1339–1344
  388. Nguyen V, Cantarovich M, Cecere R, Giannetti N. Tricuspid regurgitation after cardiac transplantation: how many biopsies are too many?. J Heart Lung Transplant. 2005;24(7 suppl):S227–S231
  389. Wiklund L, Suurkula MB, Kjellstrom C, Berglin E. Chordal tissue in endomyocardial biopsies. Scand J Thorac Cardiovasc Surg. 1994;28:13–18
  390. Mielniczuk L, Haddad H, Davies RA, Veinot JP. Tricuspid valve chordal tissue in endomyocardial biopsy specimens of patients with significant tricuspid regurgitation. J Heart Lung Transplant. 2005;24:1586–1590
  391. Levi DS, DeConde AS, Fishbein MC, et al. The yield of surveillance endomyocardial biopsies as a screen for cellular rejection in pediatric heart transplant patients. Pediatr Transplant. 2004;8:22–28
  392. Billingham ME, Cary NR, Hammond ME, et al. A working formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection: Heart Rejection Study Group (The International Society for Heart Transplantation). J Heart Transplant. 1990;9:587–593
  393. Winters GL. The challenge of endomyocardial biopsy interpretation in assessing cardiac allograft rejection. Curr Opin Cardiol. 1997;12:146–152
  394. Cai J, Terasaki PI. Humoral theory of transplantation: mechanism, prevention, and treatment. Hum Immunol. 2005;66:334–342
  395. Delgado JF, Sanchez V, de la Calzada CS. Acute rejection after heart transplantation. Expert Opin Pharmacother. 2006;7:1139–1149
  396. Bierl C, Miller B, Prak EL, et al. Antibody-mediated rejection in heart transplant recipients: potential efficacy of B-cell depletion and antibody removal. Clin Transpl. 2006;489–496

 Reprint requests: Amanda W. Rowe, International Society for Heart and Lung Transplantation, 14673 Midway Road, Suite 200, Addison, TX 75001. Telephone: 804-873-2541. Fax: 817-912-1237.

 E-mail address: susie.newton@ishlt.org; amanda.rowe@ishlt.org

PII: S1053-2498(10)00358-X

doi: 10.1016/j.healun.2010.05.034

The Journal of Heart and Lung Transplantation
Volume 29, Issue 8 , Pages 914-956 , August 2010

Article Tools

* Image Usage & Resolution